These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12879831)

  • 1. Understanding why GPs see pharmaceutical representatives: a qualitative interview study.
    Prosser H; Walley T
    Br J Gen Pract; 2003 Apr; 53(489):305-11. PubMed ID: 12879831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting feasibility and acceptability of a practice-based educational intervention to support evidence-based prescribing: a qualitative study.
    Watkins C; Timm A; Gooberman-Hill R; Harvey I; Haines A; Donovan J
    Fam Pract; 2004 Dec; 21(6):661-9. PubMed ID: 15528289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in prescribing between GPs: impact of the cooperation with pharmacists and impact of visits from pharmaceutical industry representatives.
    Muijrers PE; Grol RP; Sijbrandij J; Janknegt R; Knottnerus JA
    Fam Pract; 2005 Dec; 22(6):624-30. PubMed ID: 16055474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pharmaceutical representative visits on GPs' drug preferences.
    Søndergaard J; Vach K; Kragstrup J; Andersen M
    Fam Pract; 2009 Jun; 26(3):204-9. PubMed ID: 19273463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Attitudes of general practitioners to pharmaceutical sales representatives in Sousse].
    Ben Abdelaziz A; Harrabi I; Rahmani S; Ghedira A; Gaha K; Ghannem H
    East Mediterr Health J; 2003; 9(5-6):1075-83. PubMed ID: 16450540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General practitioners' perceptions of continuing medical education's role in changing behaviour.
    Goodyear-Smith F; Whitehorn M; McCormick R
    Educ Health (Abingdon); 2003 Nov; 16(3):328-38. PubMed ID: 14741881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bowel cancer screening in England: a qualitative study of GPs' attitudes and information needs.
    Woodrow C; Rozmovits L; Hewitson P; Rose P; Austoker J; Watson E
    BMC Fam Pract; 2006 Sep; 7():53. PubMed ID: 16981989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes of general practitioners in New Zealand to pharmaceutical representatives.
    Thomson AN; Craig BJ; Barham PM
    Br J Gen Pract; 1994 May; 44(382):220-3. PubMed ID: 8204336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of the range of drugs prescribed in general practice: a cross-sectional analysis.
    de Bakker DH; Coffie DS; Heerdink ER; van Dijk L; Groenewegen PP
    BMC Health Serv Res; 2007 Aug; 7():132. PubMed ID: 17711593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A qualitative study exploring how GPs decide to prescribe antidepressants.
    Hyde J; Calnan M; Prior L; Lewis G; Kessler D; Sharp D
    Br J Gen Pract; 2005 Oct; 55(519):755-62. PubMed ID: 16212850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General Practitioners with special clinical interests: a qualitative study of the views of doctors, health managers and patients.
    Boggis AR; Cornford CS
    Health Policy; 2007 Jan; 80(1):172-8. PubMed ID: 16621121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attitudes of general practitioners to their interactions with pharmaceutical companies: a qualitative study.
    Quinn RJ; O'Neill C
    Ir Med J; 2002; 95(7):199-202. PubMed ID: 12227525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informed consent? How do primary care professionals prepare women for cervical smears: a qualitative study.
    Chew-Graham C; Mole E; Evans LJ; Rogers A
    Patient Educ Couns; 2006 Jun; 61(3):381-8. PubMed ID: 15964735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of pharmaceutical representative visits and medication samples in community-based family practices.
    Backer EL; Lebsack JA; Van Tonder RJ; Crabtree BF
    J Fam Pract; 2000 Sep; 49(9):811-6. PubMed ID: 11032205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Insufficient communication and information regarding patient medication in the primary healthcare].
    Bakken K; Larsen E; Lindberg PC; Rygh E; Hjortdahl P
    Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1766-9. PubMed ID: 17599123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan.
    Rohra DK; Gilani AH; Memon IK; Perven G; Khan MT; Zafar H; Kumar R
    J Pharm Pharm Sci; 2006; 9(1):50-9. PubMed ID: 16849008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Family doctors' views of pharmaceutical sales representatives: assessment scale development.
    Kersnik J; Klemenc-Ketis Z; Petek-Ster M; Tusek-Bunc K; Poplas-Susic T; Kolsek M
    Fam Pract; 2011 Aug; 28(4):456-60. PubMed ID: 21292626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors.
    Edwards D; Ballantyne A
    Intern Med J; 2009 Mar; 39(3):191-6. PubMed ID: 19383067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge of drug costs: a comparison of general practitioners in Scotland and England.
    Ryan M; Yule B; Bond C; Taylor R
    Br J Gen Pract; 1992 Jan; 42(354):6-9. PubMed ID: 1586545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [GPs' perceptions of the Institute for Rational Pharmacotherapy].
    Gudex C; Hoffmann M; Brørs O; Dahlqvist R
    Ugeskr Laeger; 2009 Feb; 171(7):522-6. PubMed ID: 19210936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.